Fiscal Wizard · Single-issue tearsheet

TMO / May 12, 2026 Run #8

TMO

Thermo Fisher Scientific Inc.

Diagnostics & Research

Composite verdict

F 20.6 / 100

Weak across fundamentals and technicals.

Industry rank 9th of 14 in Diagnostics & Research

industry=Diagnostics & Research

Fundamentals Weak

35.5 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 34 metrics shown.

Strongest
Weakest
Cash Conversion 88
PEGY 0
Capex to Sales 75
PEG 0
Net Margin 75
Total Shareholder Yield 0

Technicals Weak

5.7 / 100

Bearish setup leads (Fibonacci Retracement, Trendline Break, MA Rejection); bulls voided by gates. · 26 signals shown.

Strongest
Weakest
OBV Divergence 50
Fibonacci Retracement 1
Double 7s 41
Trendline Break 11
Pin Bar 40
MA Rejection 15

Risk Gates

2 blocking 5 caution

2 gates blocking, 11 signals voided.

  • MA Crossover voids RSI Divergence, MACD Divergence +9
  • Regime Filter voids RSI Divergence, MACD Divergence +9
  • Debt-to-Assets caution band
  • Interest Coverage caution band

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for TMO.